Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)